* DarioHealth Corp DRIO.OQ DRIO.O is expected to show a
fall
in quarterly revenue when it reports results on March 28 for
the period ending December 31 2023
* The New York City-based company is expected to report a
47.5% decrease in revenue to $3.572 million from $6.81 million a
year ago, according to the mean estimate from 2 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for DarioHealth Corp is for
a loss
of 54 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for DarioHealth
Corp
is $5.25, above its last closing price of $1.49.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.48 -0.46 -0.49 Missed -6.5
Jun. 30 2023 -0.57 -0.52 -0.58 Missed -11.1
Mar. 31 2023 -0.49 -0.50 -0.45 Beat 9.6
Dec. 31 2022 -0.56 -0.65 -0.51 Beat 21.8
Sep. -0.71 -0.76 -0.64 Beat 16.1
30 2022
Jun. 30 2022 -0.71 -0.71 -0.74 Missed -3.9
Mar. 31 2022 -0.96 -0.96 -0.74 Beat 22.7
Dec. 31 2021 -1.09 -1.06 -1.09 Missed -3.2
This summary was machine generated March 26 at 12:46 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)